Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Carl Gordon bought 71,367 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were purchased at an average cost of $7.53 per share, for a total transaction of $537,393.51. Following the acquisition, the director directly owned 5,189,871 shares in the company, valued at $39,079,728.63. This trade represents a 1.39% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
Electra Therapeutics Trading Down 7.8%
NASDAQ ETRA traded down $0.62 on Thursday, hitting $7.35. The stock had a trading volume of 524,786 shares, compared to its average volume of 481,923. Electra Therapeutics, Inc. has a 52-week low of $6.86 and a 52-week high of $15.50.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on ETRA. Jefferies Financial Group initiated coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued a “buy” rating and a $32.00 price objective on the stock. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. TD Cowen started coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating for the company. Zacks Research upgraded Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. Finally, HC Wainwright started coverage on Electra Therapeutics in a report on Monday, October 26th. They issued a “buy” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $33.50.
View Our Latest Stock Analysis on Electra Therapeutics
About Electra Therapeutics
Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.
Electra’s lead investigational product is ELA026, an antibody targeting SIRPĪ±, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.
Featured Articles
- Five stocks we like better than Electra Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
